slides · global inventory
Summarize
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,035
Current window 18,661-18,690
Pages 1,402
Rows per page 30
Slide function
18,661-18,690 of 42,035
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
253
The slide presents a qualitative anecdote from a physician interview regarding drug safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
279
The slide highlights key negative sentiment regarding market saturation and physician adoption hurdles.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
06
The slide functions as a detailed table of contents with summaries for each section.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
08
The slide outlines a bearish thesis on Lasertec, citing market saturation and the impending entry of a superior competitor (KLA).Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
09
The slide functions as a detailed TOC/summary of specific investigative findings.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
113
The slide is a Q&A transcript format. It highlights the technical barriers to entry (Die-to-Database) that sustain KLA's market position.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
291
The slide presents expert testimony defending KLA's non-actinic inspection technology against competitors.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
05
The slide details the mechanism of inventory manipulation to inflate profits, comparing the scale of the alleged fraud to historical cases like Olympus and Toshiba.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Loop · Logic Chain1 hit
13
Contains testimonials from former field service engineers regarding Lasertec's ACTIS A150 equipment and Ushio light sources.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
15
This slide presents qualitative evidence from industry insiders (former KLA engineers, semiconductor executives) regarding Lasertec's product reliability issues.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
22
The slide details interviews with former Cymer and Isteq experts, contrasting Lasertec's resource allocation with ASML's massive investment in EUV technology.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
24
Contains specific allegations regarding Lasertec's supply chain, Isteq's origins, and technical failures of the plasma-based light source.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
25
This slide presents a critical investigative summary regarding Lasertec's technical claims and customer relations.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
26
ページ番号26。第6部（185-191ページ）の要約。Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · Problem & ComplicationLoop · Logic Chain1 hit
06
The slide uses aggressive, highly critical language to frame the upcoming sections of the report.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
07
This is a continuation of a larger table of contents, starting at item 13.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
08
This slide appears to be a continuation of a larger table of contents, starting at page 18.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
41
The slide uses a combination of analyst commentary and a direct testimonial to frame the company as a 'one-trick pony' in decline.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
42
The slide uses strong, accusatory language typical of activist short reports.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
44
This slide is part of an activist short report, focusing on product failure and management deception.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
45
This is an activist short-seller report slide. It uses anecdotal evidence from KOLs to build a narrative of systemic failure.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
46
This slide uses strong, accusatory language typical of activist short-seller reports to frame the company's culture and market position.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
47
This slide uses qualitative evidence from KOLs and ex-employees to build a narrative of corporate failure.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
49
This is a text-heavy slide summarizing negative findings from expert interviews (KOLs and former executives).Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Struggle1 hit
50
The slide uses anecdotal evidence from former executives to build a bearish case against Nevro's turnaround and acquisition potential.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The StruggleLoop · Cost Of Inaction1 hit
51
This slide uses aggressive, activist-style language to frame Nevro as a failing company and Saluda as a disruptive competitor.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit